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 Abstract 
Objective 
The objective of this selective EBM review is to determine whether or not transcutaneous vagal 
nerve stimulation is an effective measure in reducing seizure frequency in adult patients with 
pharmacoresistant epilepsy. 
Study Design 
This systematic review comprises a randomized controlled trial and an observational pilot study, 
both published in 2014, as well as a double-blind randomized control trial published in 2016. 
Data Sources 
All articles were published and displayed in English. The articles were obtained via the PubMed 
database. 
Outcomes Measured 
Reductions in average seizure frequency were analyzed based on data from patient seizure 
diaries.6,7,8 Secondary outcomes, including quality of life and seizure severity, were measured 
through the Quality of Life in Epilepsy-31 (QoLIE-31) and Liverpool Seizure Severity Scale 
(LSSS), respectively.6,7,8 
Results 
Aihua et al. and Peijing et al. demonstrated a significant reduction in seizure frequency, as well 
as significant improvements in QoLIE-31 and LSSS scores.6,8 Bauer et al. did not achieve 
statistically significant reductions in seizure frequency compared to the control, nor did they 
demonstrate significant improvements in the QoLIE-31 or LSSS scores.7 
Conclusion 
The results evaluated in this systematic review showed promise for the use of tVNS in the 
treatment of pharmacoresistent epilepsy. However, due to conflicting data and study design 
limitations, no definitive conclusion could be achieved at this time. Further study is required to 
better characterize the efficacy of tVNS in reducing seizure burden. 
Key Words 
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Introduction 
Seizures are a condition of aberrant electrical activity in the brain which disrupt normal 
physiologic processes. A person is considered to have epilepsy when multiple seizures occur 
without an identified and reversible cause, such as alcohol withdrawal.1 While 5-10% of the 
population will experience a seizure in their lifetime, only about 0.3-0.5% are affected by 
epilepsy.2 Not only is this disease fairly common, it also carries a significant financial burden. A 
2015 systematic review found annual per-patient epilepsy costs ranged from $1,022-19,749.3 
Those with refractory disease are affected to an even greater degree, with costs over twice as 
high as those with controlled epilepsy.4 Refractory patients also average 3.6 annual visits for 
their epilepsy, compared to 2.2 for controlled, and are hospitalized roughly twice as often.4  
The etiology of seizures is diverse and largely varies by age. Febrile seizures are most common 
among young children and epilepsy in older children is often due to anatomical abnormalities or 
developmental disorders.2 In adults and the elderly, head trauma and stroke are the most common 
causes, respectively.2 Other causes include neoplasms, infections, metabolic disturbances and 
autoimmune disorders.1 Only 10% of epileptics have generalized tonic-clonic seizures as their 
main presentation.2 Others with generalized seizures present with brief impairment of 
consciousness, as seen in absence seizures, or may have myoclonic or atonic episodes. Seizures 
may also have a focal onset, which may cause motor symptoms or sensory abnormalities and 
may or may not impair consciousness. Focal seizures also possess the potential to disseminate 
from the affected area to both cerebral hemispheres, producing a generalized seizure.  
The cornerstone of epilepsy treatment is prophylactic antiepileptic medications. While 
indications for medications vary by seizure classification, common medications include 
valproate and lamotrigine.4 Surgical resection of the problematic areas of the brain remains an 
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option for those who have failed at least two medications.1 For those without well-defined 
seizure foci, or that are poor surgical candidates, surgically implanted vagal nerve stimulation 
(iVNS) exists.1 iVNS was approved by the FDA in 1997 and has been demonstrated to be a safe 
and effective treatment, though is not without adverse reactions.5 The most common reactions 
include cough and voice hoarseness5,6, but vocal cord paralysis and device infection remain rare 
complications5. Transcutaneous VNS (tVNS) circumvents these adverse reactions by stimulating 
the somatic branch of the vagus nerve via the Ramsay-Hunt zone of the ear.6 tVNS also avoids 
the need for invasive surgical implantation and periodic battery replacements.6,7,8 
Objective 
The objective of this selective EBM review is to determine whether or not transcutaneous vagal 
nerve stimulation is an effective measure in reducing seizure frequency in adult patients with 
pharmacoresistant epilepsy. 
Methods 
The population of interest consists of men and women of at least 18 years of age with 
pharmacoresistent epilepsy. This review compares tVNS to either stimulation of a non-
therapeutic zone of the ear or to stimulation at a sub-therapeutic frequency. The efficacy of tVNS 
was primarily evaluated via reduction in seizure frequency and secondarily through quality of 
life improvement and reduction in symptom severity.  
The Cochrane and Medline database searches were used to find articles relevant to the clinical 
question that contained patient-oriented outcomes. Keywords used in searching included 
epilepsy, seizures, transcutaneous electric nerve stimulation and vagus nerve stimulation. This  
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Table 1: Demographics and Characteristics of Selected Studies 
Study Type # 
Pts 
Age (yrs) Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Aihua, 
20146 
RCT 60 Treatment 
group 
mean: 34.5 
(IQR 26.5, 
41.3) 
Control 
group 
mean: 
29.0 (IQR 
24.5, 42.0) 
> 4 years of age 
> 4 seizures per 
month 
Taking ≥ 2 AEDs 
over 2 years with 
ineffective seizure 
control 
Unable or unwilling 
to complete surgical 
treatment 
 
Pregnant 
Lactating 
Serious heart, liver 
or kidney disease 
Implanted medical 
devices 
Could not tolerate t-
VNS for more than 6 
months 
 
13 Bilateral 
Ramsey-Hunt 
zone tVNS  
 
vs 
 
Bilateral 
earlobe tVNS  
 
Bauer, 
20167 
RCT, 
double-
blind 
76 18-65, 
mean 38.8 
± 12.5 
Age 18-65 years 
Have epilepsy with 
focal and/or 
generalized seizures 
≥ 3 seizures per 
month 
Stable regiment of ≤ 
3 AEDs for ≥ 5 
weeks 
 
≤ 21 consecutive 
seizure-free days 
> 1 episode of status 
epilepticus within 6 
months 
Current or prior 
treatment with iVNS 
or DBS 
Ablative epilepsy 
surgery 
History of non-
epileptic seizures 
Major Psychiatric 
disorders 
Deteriorating 
neurological or 
medical conditions 
and/or relevant 
cardiovascular 
disease 
 
18 Therapeutic 
unilateral 
tVNS at 25 Hz 
 
vs 
 
Subtherapeutic 
unilateral 
tVNS at 1 Hz  
(active control) 
 
 
Peijing, 
20148 
Observa
tional 
Pilot 
Study 
50 25.2 ± 13.1 Age 12-65 years 
Frequent disabling 
seizures, intractable 
to treatment with ≥ 
1 AEDs for ≥ 1 year 
Bilateral and/or non-
localized findings, 
not candidates for 
surgical treatment 
Valid record of the 
patient’s daily 
frequency of 
seizures 
Tumors, progressive 
encephalopathy, 
progressive 
neurodegenerative 
disorders and serious 
pulmonary and heart 
disease 
Patients treated 
concomitantly with 
corticosteroids, 
anxiolytics or 
antidepressants 
 
3 Triangular 
fossa of the 
auricle 
Transcutaneou
s electrical 
nerve 
stimulation 
(TENS)  
 
(no 
comparison, 
observational 
study) 
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systematic review is comprised of a randomized controlled trial, a randomized double-blind 
controlled trial and an observational pilot study. All evaluated articles were displayed in English 
and contained published data. Inclusion criteria in the search included randomized controlled 
trials or observational studies published between 2007 and the time of writing. Exclusion criteria 
included studies with fewer than 50 participants. Reported statistics used include P-values, CIs 
and mean change from baseline. 
Outcomes Measured 
The primary outcome measured in all articles was reduction in seizure frequency.6,7,8 This was 
evaluated through seizure diaries kept by the patients and reported through surveys8 or follow-up 
telephone correspondence6. Changes in quality of life were monitored through the Quality of 
Life in Epilepsy-31 (QoLIE-31). This questionnaire utilizes a health-focused perspective, with 
scores ranging from 0% to maximal quality of life at 100%.7 Changes in symptom severity were 
monitored through the Liverpool Seizure Severity Scale (LSSS). As the name suggests, this 20-
question survey assesses seizure symptoms, with maximal symptoms given a score of 80.7  
Results 
Aihua et al. published a randomized controlled trial in 2014 in which 81 patients with 
pharmacoresistent seizures were selected from Xuanwu Hospital in China. Patients were required 
to have taken at least 2 antiepileptic drugs (AEDs) for at least 2 years with poor results and in 
which surgery was not an option.6 Patients excluded from the study totaled 21, another 5 were 
lost to follow up and an additional 8 discontinued due to adverse reactions.6 Of the 47 that 
completed the study, 25 were female and 22 were male.6 Full inclusion and exclusion criteria 
may be found in Table 1. The average age of the treatment and control groups were 34.5 (IQR: 
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26.5 - 41.3) and 29.0 (IQR: 24.5 - 42.0), respectively.6 The most common seizure type was 
simple partial at 68.1% of the study population.6 Complex partial seizures accounted for another 
12.8%, and 19.1% had generalized seizures.6 The average length of epilepsy diagnosis, in years, 
was 19.7 ± 11.1 in the treatment group and 17.6 ± 9.6 in the control group.6 Baseline seizure 
frequency was 6.0 (IQR: 4.8 - 25.0) for the treatment group and 7.0 (IQR: 4.0 - 11.5) in the 
control group.6 Each group was randomly assigned 30 patients.6 Those receiving treatment 
underwent bilateral stimulation of the Ramsay Hunt zone of the ear at a frequency of 20 Hz with 
a 0.2 s pulse width.6 Current was titrated up from 2 mA, as dictated by patient tolerance.6 
Stimulation was continuous for 20 minutes, three times daily for 12 months.6 Control group 
patients received the same stimulation, but of the earlobe.6 All patients were maintained on their 
baseline antiepileptic regimen.6 
The researchers found a significant reduction in seizure frequency, with median values at 5.5 
(IQR: 3.0 - 12.0) at 6 months and 4.0 (IQR: 2.8 - 8.3) at 12 months.6 Despite these results, a 
significant difference between the treatment and control groups was not observed until 12 
months, where median seizure frequency was 4.0 (IQR: 2.8 - 8.3) and 8.0 (IQR: 4.5 - 12.0), 
respectively.6 Results are summarized in Table 2. Significant improvements were also observed 
in QoLIE-31 and LSSS scores after 12 months of treatment (P < 0.001, P = 0.001), though the 
data were not published.6 
Table 2: Reduction in Seizure Frequency in the Aihua Study6 
Duration of 
Therapy 
Median Seizure 
Frequency 
Percent Reduction from 
Baseline 
P Value 
6 Months 5.5 (IQR 3.0 - 12.0) 8.3% P < 0.001 
12 Months 4.0 (IQR 2.8 - 8.3) 33% P < 0.001 
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In 2016, Bauer published a double-blind randomized controlled trial that included 87 patients 
from Germany and Austria.7 Selected patients had to have at least 3 monthly seizures and no 
seizure-free period of greater than 21 days.7 Screening parameters deselected 11 patients and an 
additional 18 discontinued the study due to non-compliance, withdrawal of consent, patient risk, 
death or various other reasons.7 Full inclusion and exclusion criteria may be found in Table 1. 
The mean age in years of the treatment group was 40.1 ± 12.7, compared to 37.5 ± 12.2 for the 
control group.7 Partial seizures accounted for 71.1% of the patients.7 The average length of 
epilepsy diagnosis was 23 years for the treatment group and 24.2 years for the control group.7 Of 
those initially enrolled in the study, 45 were female and 31 were male.7 Patients were randomly 
selected into the treatment and control groups, which initially contained 37 and 39 patients, 
respectively.7 Those enrolled in the treatment group were subjected to unilateral stimulation at 25 
Hz with a 0.25 s pulse width at cycles of 30 seconds on and 30 seconds off.7 Stimulation was 
continued as described above for 4 hours daily for 20 weeks.7 Patients enrolled in the control 
group received equivalent stimulation, but at a sub-therapeutic frequency of 1 Hz.7 Current was 
titrated between perception of the stimulation and painful stimulation to an average of 1.02 ± 
0.83 mA in the control group and 0.50 ± 0.47 mA in the treatment group.7 The antiepileptic 
regimen of the patients remained constant throughout the study.7 Statistics were analyzed using 
the ANCOVA model.7 Median compliance was found to be 93.3% for the control group and 
96.7% for the treatment group.7 
The study found LS-mean reductions in seizure frequency of approximately -2.9% (95% CI:      
[-26.4%; 21.5%], p = 0.842) in the control group and 22.9% (95% CI: [-1.7%; 47.5%], P = 
0.067) in the treatment group.7 Neither of these values demonstrated clinical significance.7 
However, a significant reduction of 34.2% (P = 0.034) was observed in the 26 patients who 
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completed the 20 weeks of stimulation.7 A 25.3% (95% CI; [-9.0%; 59.7%], P = 0.146) 
difference in LS-mean was observed between the control and treatment groups at end of 
treatment, though this value was also found to be insignificant.7 Results are summarized in Table 
3. Average LSSS scores increased by 0.83 in the control group and 1.56 in the treatment group, 
though only the change in the treatment group was found to be significant.7 No significant 
difference was found between the groups.7 The QoLIE-31 values were also found to have 
increased throughout the study by 4.65 and 2.68 in the control and treatment groups, 
respectively.7 Only the control group difference was found to be significant.7 Again, no 
difference was found between the groups.7 Results are summarized in Table 4. 
Table 3: Reduction in Seizure Frequency in the Bauer Study7 
Group LS-Mean Reduction in Seizure 
Frequency at 20 Weeks 
95% CI P Value 
Control -2.9% [-26.4%; 21.5%] P = 0.842 
Treatment 22.9% [-1.7%; 47.5%] P = 0.067 
 
Table 4: Change in LSSS and QOLIE-31 Scores at End of Treatment in the Bauer Study7 
Group Change in LSSS Score 
at End of Treatment 
P Value Change in QoLIE-31 
Score at End of 
Treatment 
P Value 
Control 0.83 P = 0.194 4.65 P = 0.01 
Treatment 1.56 P = 0.017 2.68 P = 0.077 
 
Published in 2014, Peijing et al. conducted an observational pilot study with 50 patients from 
three Chinese hospitals.8 Patients included in the study had to have pharmacoresistent seizures 
while taking at least 2 AEDs for at least 1 year.8 Full inclusion and exclusion criteria may be 
found in Table 1. Over the course of the study, 3 discontinued due to adverse reactions.8 Of the 
47 that completed the study, 28 were male and 19 were female.8 The average age of those 
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participating in the study was 25.2 ± 13.1 years.8 84% of the participants suffered from complex 
partial seizures, with the remaining 16% suffering from generalized seizures.8 The average 
length of diagnosis of epilepsy was 12.0 ± 8.1 years and the average monthly seizure frequency 
was 85.2 ± 14.4.8 All patients underwent unilateral stimulation of the triangular fossa of the 
auricle for 30 minutes, twice daily, for a total of 24 weeks.8 Stimulation was accomplished at a 
frequency of 20-30 Hz with a ≤ 1 ms pulse width and at 1 mA of current.8 Patients were 
maintained on their baseline AED treatment for the duration of the study.8  
The authors found a significant decrease in average seizure frequency of 51.3% (P < 0.01) after 
24 weeks of treatment.8 This was improved from 46.6% (P < 0.01) at 16 weeks and 34.3% (P < 
0.05) at 8 weeks of treatment.8 Significant improvement was also observed in the QOLIE-31 
scores, with an increase of 4.4 (P < 0.001) at the end of treatment.8 Similarly, significant 
improvements were seen in LSSS scores (P < 0.017), though the data were not reported.8 
Table 5: Reduction in Seizure Frequency in the Peijing Study8 
Duration of Therapy Reduction in Seizure Frequency from Baseline P Value 
8 Weeks 34.3% P < 0.05 
16 Weeks 46.6% P < 0.01 
24 Weeks 51.3% P < 0.01 
 
Overall, tVNS was well tolerated over all three studies. Aihua et al. had 1 patient discontinue due 
to dizziness and had 3 experience daytime drowsiness.6 Bauer et al. found headache to be the 
most common treatment emergent adverse reaction.7 Other common reactions included ear pain, 
erythema, fatigue, vertigo and nausea.7 A summary of all adverse reactions from this study is 
detailed in Table 6. A total of 4 control group participants discontinued due to syncope, 
palpitations, erythema and exacerbation of seizures.7 Another 3 treatment group participants 
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discontinued due to vestibular neuronitis, basal cell carcinoma and headache/exhaustion/nausea.7 
One patient passed away after a sudden unexplained death in epilepsy (SUDEP), which was 
considered to be unrelated to tVNS treatment.7 Peijing et al. found similar results, with one 
patient discontinuing due to dizziness.8 Another two patients reported having erythema and 
edema.8 
Table 6: Treatment Emergent Adverse Reactions in the Bauer Study7 
Adverse Reaction Control Group (n = 39) 
N (%) 
Treatment Group (n = 37) 
N (%) 
Headache 2 (5.1) 7 (18.9) 
Ear Pain 2 (5.1) 6 (16.2) 
Erythema 1 (2.6) 3 (8.1) 
Vertigo 1 (2.6) 3 (8.1) 
Fatigue 2 (5.1) 1 (2.7) 
Nausea 1 (2.6) 2 (5.4) 
 
Discussion 
In this systematic review, the efficacy of transcutaneous vagal nerve stimulation (tVNS) was 
evaluated in the reduction of seizure frequency and improvement of quality of life in patients 
suffering from pharmacoresistent epilepsy. One of the randomized controlled trials and the 
observational pilot study found statistically significant reduction in the average seizure frequency 
of those enrolled.6,8 The double-blind RCT did not find statistically significant reductions in 
seizure frequency overall but did find significant improvements in the subset of participants that 
completed the full study period.7 Similarly, the former two studies found statistically significant 
improvements in QoLIE-31 and LSSS scores.6,8 The later study demonstrated conflicting 
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evidence, finding significant improvement of the QoLIE-31 scores only in the control group and 
statistically worse LSSS scores in the treatment group.7  
Comparing the three trials, efficacy was directly related to treatment duration.6,7,8 This suggests a 
greater benefit may be observed in patients over time as they continue with therapy. 
Interestingly, efficacy was found to be inversely related to both length of diagnosis and to 
average age of participant when comparing results to population demographics between the three 
studies.6,7,8 This may suggest tVNS therapy is more effective when started earlier in the disease 
process, when patients are younger.  
The most significant limitation of all three studies was the subjectivity of patient-recorded 
seizure diaries and surveys. The utilization of objective measures, such as ambulatory EEG 
monitoring, may yield more conclusive results in future studies. In addition, the Aihua study 
utilized bilateral stimulation, which may have magnified efficacy relative to the other studies, 
which used unilateral stimulation.6,7,8 The authors also noted the study population contained a 
sample size too small to be able to compare efficacy against various AEDs.6 The study also had a 
fairly high dropout rate at 22%, which may have impacted the end results.6 While this study 
demonstrated high precision in terms of statistical significance, the IQRs reported were wide, 
indicating substantial variability among the subjects.6 In the Bauer study, the researchers had to 
utilize higher current in the control stimulation to ensure blinding, which may have artificially 
reduced the observed difference between treatment and control groups.7 They also noted that 
while medication regimens were maintained, approximately 33% of those enrolled were not on 
an AED throughout the study, limiting the comparability to the other studies included.7 This 
study also had a high dropout rate at 24%.7 In the Peijing study, the major limitations were that 
the study was not blinded or controlled.8 
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Currently, there are no tVNS devices that are FDA approved for the treatment of seizures. This is 
reflected in the paucity of research available from the US, which was a major factor in the 
selection of studies with mainly Chinese6,8 and German7 populations. However, the gammaCore 
tVNS system was FDA approved in 2017 for cluster headaches and in 2018 for migraine 
headaches.9 The tVNS device is also currently being researched for other diagnoses, including 
heart failure10, depression11 and autism12. Alternative methods of neurostimulation are also under 
investigation, including trigeminal nerve stimulation (TNS), deep brain stimulation (DBS) and 
the responsive neurostimulation system (RNS).5  
Conclusion 
The evidence appears inconclusive as to whether tVNS is effective in reducing seizure burden in 
those with pharmacoresistent epilepsy. The Peijing and Aihua studies found significant 
reductions in average seizure frequency at end of treatment ranging from 33-51%.6,8 However, 
the Peijing study was not a randomized controlled trial8 and Bauer et al. did not observe a 
significant reduction in seizure frequency7. Nevertheless, the results are promising, and the 
Bauer study did find a significant reduction among the participants that were able to complete 
the trial.7 Due to these results and the relatively benign side effect profile, further research is 
warranted to better characterize the effectiveness of tVNS in reducing seizure burden. Future 
studies will benefit from increased sample sizes and greater diversity of geographical regions. 
Furthermore, as a direct relationship was observed between length of treatment and efficacy, 
longer trials may be necessary to observe maximal efficacy. Finally, greater standardization of 
patient demographics, study design and treatment modality may help to confirm the efficacy of 
tVNS and determine which patient populations are of greatest benefit.  
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